Skip to main content

Juan Ignacio Esteban Mur

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Juan Ignacio Esteban Mur

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Estudi de tolerància perifèrica a la proteïna no estructural NS3 del virus de l'hepatitis C (VHC) per desenvolupar immunoteràpia contra la infecció per VHC per a la prevenció de l'hepatocarcinoma

IP: Juan Ignacio Esteban Mur
Collaborators: Lluis Castells Fusté, Silvia Sauleda Oliveras, Josep Quer Sivila
Funding agency: Fundació La Marató de TV3
Funding: 165000
Reference: TV3/052310
Duration: 01/01/2006 - 31/12/2009

Selección y expansión de linfocitos T CD4+ NS3-específicos de pacientes infectados por Virus de la hepatitis C (VHC). Caracterización del estado de anergia de la infección crónica

IP: -
Collaborators: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté, Josep Quer Sivila, Juan Ignacio Esteban Mur
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 90750
Reference: SAF2006-03681
Duration: 01/10/2006 - 30/09/2009

Ministerio de Ciencia

Investigación de la tolerancia periférica a NS3 como causa de la persistencia del virus de la hepatitis C (VHC).

IP: Juan Ignacio Esteban Mur
Collaborators: Silvia Sauleda Oliveras, Josep Quer Sivila
Funding agency: Instituto de Salud Carlos III
Funding: 140024
Reference: PI030274
Duration: 01/01/2003 - 28/11/2006

Efecto de la variabilidad genética en la región NS3 del Virus de la hepatitis C (VHC) sobre maduración y presentación de proteínas recombinantes aislado-específicas de células dendríticas autólogas.

IP: -
Collaborators: Silvia Sauleda Oliveras, Josep Quer Sivila, Maria Nieves Martell Pérez-Alcalde, Juan Ignacio Esteban Mur
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 164600
Reference: SAF2003-08724
Duration: 15/12/2003 - 15/12/2006

Ministerio de Ciencia

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Filipa Xavier De Carvalho Negrao Valente

Filipa Xavier De Carvalho Negrao Valente

Research technician
Cardiovascular Diseases
Read more
Carlos Alberto Piedra Calle

Carlos Alberto Piedra Calle

Reconstructive Surgery of the Locomotor System
Read more
Francisca Yañez Araya

Francisca Yañez Araya

Postdoctoral researcher
Physiology and Pathophysiology of the Digestive Tract
Read more
Maria Vidal Burdeus

Maria Vidal Burdeus

Cardiovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.